DIRECT CEREBRAL OXYGENATION FOR ISCHEMIC STROKE

直接脑氧合治疗缺血性中风

• 批准号: 6311388
• 负责人: Timothy J Pelura
• 金额: $ 32.01万
• 依托单位: NEURON THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-30 至 2002-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6311388
• 关键词: brain circulation; cerebral cortex; cerebral ischemia /hypoxia; cerebrospinal fluid; emulsions; fluosol; human subject; human therapy evaluation; oxygen transport; patient oriented research; respiratory oxygenation; stroke; stroke therapy

DESCRIPTION(adapted from applicant's abstract): Neuron Therapeutics, Inc. (Nfl) is developing a perfluorocarbon-containing artificial cerebrospinal fluid (Revoxyn) that can deliver oxygen and other nutrients directly to brain tissue even when vessels are occluded and cerebral blood flow compromised by ischemic stroke, a "brain attack." Preclinical studies demonstrated that ventricular perfusion with Revoxyn reduces infarct volume by >90 percent and reverses loss of EEG activity. In Phase I of this FAST TRACK SBIR application NTI will: 1) determine whether single pass perfusion with Revoxyn delivered via the ventricle-to-lumbar spine route is safe for patients with severe hemispheric ischemic stroke; 2) determine to what extent the composition of Revoxyn changes during cerebral perfusion in man; and 3) design, fabricate, and test on the lab bench a prototype recirculating perfusion device suitable for preclinical safety testing in vivo. Feasibility will be demonstrated if 1) the Revoxyn single pass perfusion system is safe in man; 2) '75 percent of input perfluorocarbon is recovered in the lumbar fluid; 3) the recirculating RDS-alpha prototype can a) reliably maintain pH, C02 and 02 tensions of conditioned Revoxyn within specifications for 24 h; b) run unattended without shutdown for 24 h; c) successfully prevent delivery of Revoxyn at pressures >25 torr under conditions of outflow restriction. PROPOSED COMMERCIAL APPLICATION: Not Available

描述（改编自申请人的摘要）：Neuron Therapeutics，Inc。（NFL） 正在开发含有全氟的人工脑脊液 （voxyn）可以将氧气和其他营养直接传递到脑组织 即使血管被遮住并被缺血损害的脑血流损害 中风，“大脑攻击”。临床前研究表明心室 用旋转的灌注将梗塞量减少> 90％，并逆转损失 脑电图活动。 在此快速轨道SBIR应用程序的第一阶段中NTI将：1）确定是否确定是否 通过心室到宽头脊柱传递的单次灌注，带有voxyn 对于严重半球缺血性中风的患者，路线是安全的。 2） 确定大脑期间旋光性变化的组成在多大程度上 人类灌注； 3）在实验室台上设计，制造和测试A 原型循环灌注装置适合临床前安全 在体内进行测试。如果1）旋转单次通行证，将证明可行性 灌注系统对人是安全的。 2）'75％的输入全氟碳是 在腰液中回收； 3）循环RDS-Alpha原型可以a） 可靠地维持pH，C02和02条件紧张 24小时的规格； b）在24小时内无人看管的无人看管； c） 在条件下成功防止在压力> 25托尔的压力下递送旋转 流出限制。 拟议的商业应用： 无法使用